TP53 and glioblastoma: Inhibition of the p53–MDM2 interaction can prevent p53 degradation and restore p53 transcriptional activity, leading to the p53-mediated induction of tumour cell apoptosis, thus making the p53–MDM2 complex a promising target for glioblastoma expressing wild type p53 [15,16,17].